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The guidelines project is a joint initiative of the Associação 
Médica Brasileira and the Conselho Federal de Medicina. 
It aims to collect information to standardize decisions and 
help create strategies during diagnosis and treatment. These 
data were prepared and are recommended by the Associação 
Brasileira de Hematologia, Hemoterapia e Terapia Celular 
(ABHH). Even so, all possible decisions should be evaluated 
by the physician responsible for diagnosis and treatment 
according to the patient’s setting and clinical status.
Description of the evidence collection method
The members of the ABHH Committee responsible for 
writing the diagnostic and treatment guidelines for acute 
promyelocytic leukemia (APL) prepared the main questions 
related to clinical diagnosis and treatment. Eighteen questions 
were structured using the Patient/Problem, Intervention, 
Comparison and Outcome (PICO) system. The search strategy, 
with specific clinical questions (Appendix 1), was applied to the 
key scientific databases (MEDLINE PubMed, Embase, SciELO, 
Lilacs and Cochrane Library). The retrieved articles were 
submitted to a critical appraisal and categorized according 
to the strength of evidence, giving support to elaborate 
the answers to the questions. Each selected reference was 
classified according to the degree of recommendation using the 
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Oxford Classification. Each recommendation was discussed by 
the committee and a consensus attained. The development of 
these recommendations was completely supervised by experts 
on evidence-based guidelines.
Recommendation degree and evidence level
A: Experimental or observational studies of better 
consistency
B: Experimental or observational studies with less 
consistency
C: Case reports (uncontrolled studies)
D: Opinion without critical evaluation based on consensus, 
physiological studies or animal models
Aims
To define parameters for clinical diagnosis, assess the severity 
and standardize steps and options for treatment, maintenance 
and monitoring of patients with acute promyelocytic leukemia 
(APL).
Which methods are used to confirm the diagnosis 
of acute promyelocytic leukemia?
P – Acute promyelocytic leukemia
I – Karyotyping, cytogenetics, flow cytometry, fluorescence 
in situ hybridization, reverse transcriptase polymerase chain 
reaction or bone marrow cell morphology
O – Diagnosis
The classic form of APL, according to World Health 
Organization (WHO) criteria, presents a characteristic 
translocation, t(15;17)(q22;q12), the PML-RARα fusion transcript 
(D).1 However, variant chromosomal aberrations are identified 
in up to 5% of APL cases including, t (11; 17)(q23; q21), t (5;17)
(q35; q12-21), t (11; 17)(q13; q21) and der (17), in which the 
retinoic acid receptor alpha (RARα) gene is fused to the PLZF, NPM, 
NuMA and STAT5b genes, respectively. PLZF-RARα, in general, 
presents atypical morphology compared to the classic PML-
RARα fusion transcript, with regular nuclei and hypogranular 
or microgranular cells, abundant cytoplasm, blasts with more 
condensed chromatin, absence of Auer rods and an increase in 
the number of pseudo-Pelger-Huet cells. The different variants 
of APL, although rare, are challenging for early diagnosis, which 
is achieved with the combination of morphological analysis, 
clinical presentation and genetic testing2 (C). There are rarer 
situations in which rearrangements of the RARα gene are 
masked or complex; these are only characterized by G-banded 
karyotyping, with fluorescence in situ hybridization (FISH) and/
or polymerize chain reaction (PCR) required for confirmation. 
Furthermore, in 20 to 40% of cases of APL, in additional to 
the t (15; 17) mutation, other clonal changes are observed at 
diagnosis such as trisomy 8; the importance of these changes 
continue to be controversial (A).3
One antibody was investigated as a possible marker to 
diagnose APL in patients with a mean age of 35 years (range: 
9-75 years) who had the PML-RARα fusion transcript (standard 
diagnosis) identified by reverse transcriptase polymerase chain 
reaction (RT-PCR). In this work, the diagnostic efficiency of 
RT-PCR was compared with morphology, cytochemistry and 
immunofluorescence using the PG-M3 monoclonal antibody; 
the time to perform this test is two hours. Morphology alone 
enabled the correct diagnosis in 88.9% of cases with 11.1% of 
false-negative results [sensitivity: 88.9%; specificity: 57.1%; 
positive predictive value (PPV): 72.7%; negative predictive value 
(NPV): 80%; verisimilitude ratio (VR): 2.07]; the association of 
morphology with cytochemistry led to a 91.7% diagnosis rate 
with 8.3% of false negatives (sensitivity: 91.7%; specificity: 78.6%; 
PPV: 84.6%; NPV: 88%; VR: 4.28). With immunofluorescence, the 
diagnosis was correct in 94.4% of the cases with 5.6% of false 
negatives (sensitivity; 94.4%: specificity: 92.9%; PPV: 94.4%; 
NPV: 92.9%), resulting in a statistically significant difference 
in respect to the morphological evaluation in isolation (p-value 
< 0.01) (B).4
In a study with 349 patients with ages ranging from 1 to 
81 years (median: 46.2 years) not including patients with the 
variants of APL, the reaction with the anti-PML antibody was 
positive in 98.9% of cases when the test was performed using 
bone marrow aspirate and 96.9% when peripheral blood was 
used; conventional cytogenetic demonstrated the t (15; 17)(Q24; 
q21) in 91% patients and RT-PCR and FISH were positive for 
the PML-RARα rearrangement in 98% and 96% of the cases, 
respectively. The results indicate that the immunofluorescence 
reaction using the anti-PML antibody can be used as a fast 
and reliable first-line test to confirm when there is clinical or 
morphological suspicion of APL in order to expedite the start 
of treatment and prevent fatal hemorrhagic complications (B).5
FISH was employed to detect the PML-RARα rearrangement 
in APL even though it was already well known that the 
sensitivity of this technique is insufficient to detect low levels 
of the disease. Eighty-two bone marrow samples were studied 
including samples from 30 healthy bone marrow donors, 33 
patients with untreated APL, 14 patients with treated APL and 
five with variant translocations. In this study, using dual-color, 
dual fusion fluorescence in situ hybridization (D-FISH) to detect 
the PML-RARα fusion transcript and RARα gene abnormalities, 
the sensitivity was 98% and the specificity was 100%. If the 
patient has a t (15; 17), this method has an excellent analytical 
sensitivity and can detect disease if more than 0.6% of 500 
nuclei are marked. It also detects alternative translocations 
involving the RARα gene in more than 1.6% of 500 nuclei but 
not those of the PML gene. Thus, it is suggested that interphase 
FISH may be as good as conventional cytogenetics to investigate 
patients with APL. For patients with a possible diagnosis of 
APL, D-FISH would initially be indicated because of the speed 
of the test. When the results of FISH are normal, conventional 
cytogenetics would complement the investigation by detecting 
chromosomal abnormalities associated with leukemias other 
than APL or by identifying variants. According to these authors, 
except for the t (15; 17) mutation, other cytogenetic changes 
have no diagnostic or prognostic significance in APL, making 
conventional cytogenetics unnecessary when the PML-RARα 
fusion transcript is detected by FISH (A).6
Eighty-five patients diagnosed with acute myeloid leukemia 
(AML), including 15 cases of APL, were studied to evaluate the 
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diagnosis of APL using the anti-PML monoclonal antibody, 
5E10. There was agreement in respect to the detection of the 
t (15; 17) by immune fluorescence and RT-PCR in 14 out of 15 
cases (93.3%) without false positive results. The discordant case 
was a patient with a 5’ breakpoint in the PML gene that did 
not express the reciprocal t (15; 17) fusion product. According 
to these authors, in addition to the traditionally described 
techniques used for the diagnosis of APL including morphology, 
immunophenotyping, conventional cytogenetics, FISH and 
RT-PCR, immunofluorescence with anti-PML monoclonal 
antibodies (5E10) allows the diagnosis of APL in 93.3% of cases, 
similar to the rate attained by RT-PCR but with the advantage 
of being faster (B).7
The recommendation of a panel of experts of the 
European Leukemia Net includes genetic confirmation of 
the diagnosis in leukemic cells in bone marrow aspirate. 
In addition to conventional karyotyping, FISH and RT-PCR, 
immunofluorescence with anti-PML antibodies can be 
performed. Diagnosis should be confirmed by molecular 
detection of the PML-RARα fusion transcript or its molecular 
variants (D).8
A publication on APL treatment suggested that several 
techniques can be used to confirm diagnosis. G-banded 
karyotyping has the advantage of being highly specific detecting 
typical translocations and variants. However, karyotyping is not 
only costly, but it is time-consuming and does not detect cryptic 
rearrangements. RT-PCR, the gold standard test for the PML-RARα 
fusion transcript, may be performed when there is leukopenia, but 
it has the disadvantages of possible contamination and technical 
problems that can lead to false-positive and false-negative test 
results. FISH can also be performed, although this technique adds 
little to karyotyping, and RT-PCR. Immunofluorescence with 
anti-PML antibodies is fast and is positive in most patients with 
atypical breakpoints (D).9
Recommendations
The diagnosis of APL is based on an evaluation of the clinical 
presentation, morphology, immunophenotyping, karyotype, 
RT-PCR, FISH and immunofluorescence with anti-PML 
monoclonal antibodies. The redundancy of diagnostic tests is 
beneficial because of the broad and indistinct characterization 
of the disease. However with the impossibility of completing 
the full set of recommended tests, identification of the 
PML-RARα rearrangement or its product together with the 
clinical presentation, morphology and immunophenotyping 
favors the diagnosis of APL, even though some variants pass 
unnoticed using this restricted approach.
Which laboratory tests are used to evaluate 
coagulopathies in acute promyelocytic leukemia?
P – Acute promyelocytic leukemia
I – Coagulogram, D-Dimer, fibrinogen, platelets, prothrombin 
time, activated partial thromboplastin time, fibrin degradation 
products
O – Bleeding
The laboratory tests to predict bleeding in patients with 
APL are important to guide transfusion therapy. Among 
the parameters analyzed are: percentage of leukemic cells, 
leukocyte and platelet counts at diagnosis, prothrombin 
time (PT), activated partial thromboplastin time (aPTT) and 
fibrinogen levels. Bleeding was observed in patients presenting 
leukocytosis (26.73 ± 6.18 × 109/L vs. 13.03 ± 3.03 × 109/L; p-value 
= 0.026), prolonged PT (4.85 ± 0.70s vs. 2.59 ± 0.28s; p-value = 
0.002) and prolonged aPTT (3.98 ± 1.68s vs. 0.96 ± 0.93s; p-value 
= 0.017). The remaining parameters showed no significant 
differences. When the PT was ≥ 5s, there was a relative risk of 
bleeding of 6.14 with this being the most accurate parameter 
to predict a coagulopathy (B).10
One study investigated patients diagnosed with APL from 
December 1998 to March 2009 who initiated treatment with 
all-trans retinoic acid (ATRA - 45 mg/m2/day) combined with 
idarubicin [12 mg/m2/day on Day (D)1-D4] or cytarabine (100 
mg/m2 b.i.d. on D1-4) and daunorubicin (45 mg/m2/day D1-3) 
who were monitored daily to measure PT, aPTT, and lactate 
dehydrogenase (LDH), plasma fibrinogen and D-dimer serum 
concentrations (B).11 There was no significant difference 
between groups with or without bleeding for LDH (p-value = 
0.003), PT (p-value = 0.037), serum fibrinogen (p-value = 0.004) 
and D-dimer (p-value = 0.001) (B).11
In an analysis of 279 patients with APL aged from 15 to 70 
years, 6.5% had severe bleeding with the following risk factors 
being identified as pre-treatment predictors for bleeding: 
baseline fibrinogen concentration < 1 g/dL [ODDs ratio (OR): 
3.28; 95% confidence interval (95% CI): 1.17-9.19; p-value = 
0.024], white blood cell (WBC) count 20 × 109/L (OR: 3.61; 95% CI: 
1.14-11.4; p-value = 0.029) and the performance status between 
2 and 3 (OR: 3.04; 95% IC: 1.02-9.02; p-value = 0.045) (B).12
Thirty-four patients with APL aged from 8 to 66 years, 
diagnosed by morphological criteria confirmed by the presence 
of the t (15;17) or PML-RARα rearrangement and submitted to 
induction treatment with daunorubicin (50 mg/m2/day for 
four days) and ATRA [45 mg/m2/day until complete remission 
(CR)] were assessed for hemostatic abnormalities. The main 
features found were: abnormal platelet count in 91% of the 
cases (mean: 30 × 109/L; range: 3-191 x 109/L), reduced plasma 
fibrinogen concentration (≤ 100 mg/dL) in 61%, prolonged aPTT 
in 9% and prolonged PT in 44%. Episodes of severe bleedings 
occurred in 29% of the patients (B).13 There was a statistically 
significant difference in the multivariate analysis of hemostatic 
parameters comparing groups with or without severe bleeding 
only for the baseline WBC count which, when over 30 × 109/L, 
favored the development of severe bleeding (OR: 10; 95% CI: 
1.0-10.5; p-value = 0.04) (B).13
Hemorrhagic complications were observed in 89.4% of 19 
patients with APL with four deaths. The fatal hemorrhages 
were related to low levels of fibrinogen and low platelet counts. 
There was no significant difference in the baseline WBC count, 
the LDH concentration, PT and aPTT (C).14
Recommendations
WBC and platelet counts, PT and aPTT, and fibrinogen, LDH 
and D-Dimer concentrations should be investigated in the 
laboratory workup of coagulopathies in APL. However, low 
fibrinogen concentrations and prolonged PT are the parameters 
that best predict the likelihood of bleeding.
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How can the risk of relapse in patients with acute 
promyelocytic leukemia be stratified?
P – Acute promyelocytic leukemia
I – Risk stratification
O – Recurrence
The prognostic factors that influence the risk of relapse 
in APL were evaluated in a series of 217 patients aged from 
one to 74 years, diagnosed with APL and confirmed by the 
presence of the PML-RARα fusion transcript by the Gruppo 
Italiano Malattie EMatologiche dell’Adulto (GIMEMA: n = 108) 
and the Spanish Programa para el Estudio de la Terapéutica en 
Hemopatía Maligna group (PETHEMA: n = 109). The variables 
analyzed were: age, gender, hemoglobin level, leukocyte count, 
platelet count, French-American-British (FAB) subtype (typical 
or variant) and the isoforms of the PML-RARα fusion transcript 
(bcr-1, bcr-2 or bcr-3). In a univariate analysis, leukocytosis, 
thrombocytopenia and the classification of APL as typical or 
variant were significant for increased risk of relapse (p-value 
< 0.0001, p-value < 0.05 and p-value < 0.05, respectively). In 
multivariate regression analysis of relapse-free survival, the 
leukocyte and platelet counts were the only variables with 
independent prognostic value. The resulting predictive model 
for relapse-free survival allowed the classification of patients 
as low risk (leukocyte count ≤ 10 × 109/L, platelet count > 40 
× 109/L), intermediate risk (leukocyte count ≤ 10 × 109/L and 
platelet count ≤ 40 × 109/L) and high risk (leukocyte count > 10 
× 109/L) with distinct curves of relapse-free survival (p-value 
< 0.0001) (B).15
In a retrospective study with 86 adults with newly diagnosed 
APL admitted to a Chinese medical service between April 2003 
and June 2009, diagnosis was established according to the 
clinical and morphological criteria of the FAB classification 
and genetically confirmed by the presence of the t (15; 17)(q24; 
q21) by karyotyping and the PML-RARα fusion transcript by 
RT-PCR. Patients were stratified into low risk when the total 
leukocyte count was < 10 × 109/L and platelet count > 40 × 
109/L, intermediate risk when the total leukocyte count was < 
10 × 109/L and platelet count < 40 × 109/L and high risk when 
the total leukocyte count was ≥ 10 x 109/L. The mean follow-up 
was 37 months (range: 6-70 months) after induction and 
consolidation treatment when patients were in CR, the overall 
survival (OS) was 100%, 100% and 84.8%, respectively for each 
risk group, with a significant difference between high risk and 
intermediate/low risk groups (p-value = 0.0034), the event-free 
survival (EFS) rates were 100%, 94.4% and 89.7%, respectively 
and the cumulative incidence of relapse in the central nervous 
system (CNS) was 0%, 2.8% and 6.9%, respectively, with a 
significant difference between high risk and intermediate/low 
risk groups (p-value < 0.05) (B).16
In the evaluation of 36 patients with APL between 1990 and 
2002 with a median age of 37 years, the risk stratification of 
patients was made on the basis of the criteria of the Italian 
GIMEMA and the Spanish PETHEMA studies (low risk when 
the leukocyte count ≤ 10 × 109/L and the platelet count > 40 × 
109/L; intermediate risk when the leukocyte count was ≤ 10 × 
109/L and the platelet count < 40 × 109/L and high risk when 
the leukocyte count was > 10 × 109/L). The OS at 32 months 
was 66% and the disease free survival (DFS) at 42 months was 
62% with a statistically significant difference between high-risk 
patients and the low/intermediate risk groups (p-value = 0.04). 
OS and DFS were not affected by age, variants of the PML-RARα 
fusion transcript or additional karyotypic abnormalities. The 
DFS was not affected by gender, hemoglobin concentration, 
karyotype or isoforms of PML-RARα fusion gene transcript (B).17
In 2008, the results of the long-term multicenter LPA99 study 
were published by the PETHEMA Group. Between November 
1996 and June 2005, 792 patients were assessed, 732 of whom 
were eligible for the study. All patients had a diagnosis of 
APL and were inserted into the LPA96 and LPA99 protocols 
which encompassed 82 institutions in several countries. 
The accumulated incidence of relapse, DFS and OS at five 
years were 11%, 84% and 82%, respectively. At the end of the 
consolidation regimen, RT-PCR was performed to identify the 
PML-RARα fusion transcript in 448 cases; three patients in the 
high-risk group remained PCR-positive. These data corroborate 
the findings of the LPA96 study (p-value = 0.028) in which five 
of 138 eligible patients (four of 44 in the high-risk group and 
one of 97 patients at intermediary risk) presented molecular 
persistence at the end of the consolidation regimen. Strategies 
adapted to the risk of each patient, prioritizing patients at high 
risk of relapse should be the focus of future studies (B).18
Recommendations
Stratification of patients with diagnosis of APL in respect 
to risk of relapse must include the leukocyte and platelet 
counts at the time of diagnosis. Patients are considered low 
risk when, at diagnosis, the leukocyte count ≤ 10 ×109/L and 
the platelet count > 40 × 109/L, intermediate risk when the 
leukocyte count ≤ 10 ×109/L and the platelet count ≤ 40 × 109/L 
and high risk when the leukocyte count > 10 × 109/L.
How should coagulopathies in acute 
promyelocytic leukemia be treated?
P – Acute promyelocytic leukemia
I – Coagulopathy
O – Treatment
Thrombohemorrhagic syndromes remain the leading 
cause of death during induction therapy and of failure to 
obtain hematological remission in patients with APL. About 
60 to 80% of patients have some clotting disorder at diagnosis. 
Currently, mortality rates secondary to thrombohemorrhagic 
events during induction occur in around 5 to 7% of patients 
eligible for clinical studies (B).14,19,20
One study retrospectively evaluated 24 patients with 
morphologic diagnosis of APL. Historical comparisons of 
studies carried out from 1970 to 1976 compared chemotherapy 
with and without the use of prophylactic unfractionated 
heparin. Group I, consisting of seven patients with a median 
age of 47 years, received arabinosylcytosine and 6-thioguanine 
and presented CR in 14.3% of the cases with death occurring 
in 85.7% (57.1% died due to cerebral hemorrhage) during the 
induction treatment. Group II, consisting of eight patients 
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with a median age of 41 years, received arabinosylcytosine 
and daunorubicin and presented CR in 25% and death in 75% 
(62.5% by cerebral hemorrhage) during the initial treatment. 
Group III, consisting of nine patients with a median age of 
35 years, received a chemotherapy scheme similar to group II 
associated with prophylactic heparin at doses varying from 5 to 
20 U/kg/hour. This group presented CR in 77.8% and deaths in 
22.2%, all due to cerebral hemorrhage. Thus, risk reduction was 
observed in 10.7% [number needed to treat (NNT): 10] between 
Groups I and II, 63.5% (NNT: 2) between Groups I and III and 
52.8% (NNT: 2) between Groups II and III (B).21,22
Twenty-six consecutive patients with newly diagnosed APL 
or in the first relapse, with ages ranging from 14 to 54 years, 
were evaluated regarding the improvement of the coagulopathy 
after starting treatment with oral ATRA (25 to 30 mg/m2/day) or 
an intravenous infusion of 0.1% arsenic trioxide (As2O3 - 10 mL/
day). This analysis was made in the bone marrow by studying 
the release of procoagulant substances by blastic cells; a return 
to normality was detected 14 days after the start of treatment 
(p-value < 0.001). In the first week of treatment, the bleeding 
symptoms improved in both the ATRA and As2O3 Groups and 
the plasma fibrinogen concentration presented progressive 
and significant increases (p-value < 0.01 and p-value < 0.05, 
respectively) with return to normality. Moreover, the platelet 
alpha-granule membrane proteins (GMP-140), which were 
elevated prior to starting treatment, decreased significantly by 
the seventh day (p-value < 0.05 in both groups), with return 
to normality in the evaluation by the 14th day of treatment; 
the levels of soluble fibrin monomer complex (SFMC) and 
D-dimer, which were high at the beginning, showed significant 
reductions in both groups (p-value < 0.001) at the end of one 
week. However, the levels of SFMC were normal for the As2O3 
Group at 14 days and only at 21 days for the ATRA Group. 
The plasma D-dimer concentrations remained high until 
CR, but without hemorrhagic manifestations throughout the 
period (B).23 In the analysis of the plasma levels of natural 
anticoagulants and fibrinolytic proteins, protein C and protein 
S were low at the beginning of treatment but there was a 
significantly higher increase in protein C activity in the ATRA 
Group compared to the As2O3 Group (p-value < 0.001 and p-value 
< 0.01, respectively), accompanied by a slight increase in plasma 
protein C. The plasma thrombomodulin concentration, elevated 
at diagnosis, showed significant reductions in both groups 
(p-value < 0.001). The increase in tissue factor plasma inhibitor 
(TFPI) decreased during treatment, without any difference in 
the fibrinolytic system (plasminogen activity, α2-plasminogen 
inhibitor, tissue plasminogen activator, plasminogen activator 
inhibitor) in both groups (B).23 
The frequency of thrombotic events was compared 
between groups of patients treated with a regimen based on a 
combination of ATRA with an anthracycline or chemotherapy 
alone. In a retrospective study, thirty-one patients with newly 
diagnosed APL were treated with ATRA (45 to 50 mg/m2/
day) associated with idarubicin (12 mg/m2/day) for four days 
starting on the fifth day of treatment or before in cases of a 
leukocyte count > 10 × 109/L. The comparison was made with 
a group of 25 patients treated with systemic chemotherapy 
alone before ATRA was on the market. There was 16% of 
thromboembolic phenomena in both treatment groups, with 
6.5% of fatal bleeding in the group treated with ATRA plus 
chemotherapy and 8% in the group treated with systemic 
chemotherapy, without significant difference (B).22, 24,25
The role of heparin in the management of coagulopathies 
associated with APL was evaluated in a retrospective study 
of 115 patients with a median age of 36.7 years (range: 3-73 
years). Patients were treated with systemic chemotherapy 
alone, not associated with ATRA. According to the decision 
of the attending physician, heparin was used in varying doses 
and routes of administration: (subcutaneous 5000 U b.i.d. 
or intravenous 2400 to 24,000 U/day). Fresh frozen plasma, 
cryoprecipitate and platelet concentrates were used as needed 
(B).26 CR was seen for 60% of the patients with 86% in the group 
with heparin and 49% in the group without heparin (p-value = 
0.002). This difference was attributed to the reduction in the 
number of fatal hemorrhages, especially intracranial bleeding, 
in the group undergoing treatment with heparin (2.6% vs. 
22.6%; p-value < 0.005) (B).26
Recommendations
The recommended treatment for bleeding disorders in 
patients with APL is the immediate start of ATRA therapy 
with support using blood products to keep the platelet count 
above 30 × 109/L and the fibrinogen concentration above 100 
mg/dL (using concentrated platelet, fresh frozen plasma and 
cryoprecipitate transfusions). There is no evidence of benefits 
with the use of heparin.
Which anthracycline should be used in induction 
therapy for acute promyelocytic leukemia in 
terms of response rate, overall survival and 
toxicity?
P – Acute promyelocytic leukemia
I – Anthracycline (daunorubicin, doxorubicin, idarubicin or 
mitoxantrone)
O - Response rate, overall survival and toxicity
Eighty patients with morphologic diagnosis of APL were 
treated during the period from 1963 and 1971. Thirty-six 
patients were treated before 1967 with 6-mercaptopurine 
(6MP) and prednisone or 6MP, methotrexate and prednisone 
or methylglyoxal-bis (guanylhydrazone - methyl-GAG). The 
remaining 44 were treated after 1967 with daunorubicin (60 
mg/m2/day for four days) followed by a break of three days 
and another course of daunorubicin based on a cytological 
examination of the bone marrow. The CR rate was 13% for 
patients treated with other regimens and 55% for those who 
received daunorubicin. The median duration of CR was 15 days 
for the group that received other drugs and 25 months for the 
daunorubicin Group (A).27
Sixty-eight patients with cytogenetic or molecular 
diagnosis of APL, aged 60 years or older, with normal liver 
and kidney function and without severe heart disease or 
infections at diagnosis were assessed in respect to response 
to induction therapy comprising one or two cycles of systemic 
chemotherapy associated with ATRA (45 mg/m2/day) until 
CR or for a maximum of 60 days [the German Acute Myeloid 
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mg/m2/day) on D1, D2 and D3. After CR patients received two 
cycles of consolidation with daunorubicin and cytarabine, plus 
maintenance with 6MP and methotrexate for two years. The 
number of patients enrolled in the study was 576 with 92.5% 
achieving CR. In a median follow-up time of ten years, 61.7% of 
the patients remained in CR and the estimated 10-year survival 
was 77%. After maintenance therapy, 26 patients died in CR 
with two due to heart failure (B).31
The International Consortium on Acute Promyelocytic 
Leukemia evaluated 183 patients treated with a protocol similar 
to that adopted by the PETHEMA Group however idarubicin 
was replaced by daunorubicin. The dose of daunorubicin was 
equivalent to five times that of idarubicin used in the induction 
and consolidation phases of the protocol. The remission rate 
was 85% and the mortality rate during induction was 15%. The 
main causes of death were bleeding (48.1%), infections (25.9%) 
and Differentiation syndrome (18.5%). The estimated 2-year OS 
and EFS were 80% and 91%, respectively (B).20
In the analysis of 19 patients with again APL who were 
treated with a modified AIDA Protocol with mitoxantrone (10 
mg/m2 on D2, D4, D6 and D8) replacing idarubicin, associated 
with ATRA (45 mg/m2/day) until CR, eight patients had early 
death and 11 showed hematological remission after induction 
with a DFS of 82% (C).32
Recommendations
Although there is no evidence that compare the different 
anthracyclines used in the induction treatment of APL patients, 
daunorubicin and idarubicin have proven effective in respect 
to the CR and survival rates especially when associated with 
ATRA. There is no comparative data regarding late toxicity.
Is induction with arsenic trioxide superior 
to induction with all-trans retinoic acid plus 
anthracycline?
P – Acute promyelocytic leukemia
I – Arsenic trioxide or arsenicals
C – All-trans retinoic acid
Patients who received ATRA (25 mg/m2/day) until CR (Group 
1) or As2O3 (0.16 mg/kg/day) until CR (Group 2) or a combination 
of ATRA and As2O3 at similar doses (Group 3) were evaluated 
(A).33 CR rates for the three groups were statistically similar 
(Group 1 vs. Group 2: p-value = 0.548; Group 1 vs. Group 3: 
p-value = 0.972; Group 2 vs. Group 3: p-value = 0.520), with 
differences in time to obtain CR; the means were 40.5 days 
(range: 25-65 days), 31 days (range: 28-38 days) and 25.5 days 
(range: 18-35 days) for Groups 1, 2 and 3, respectively (Group 
1 vs. Group 2: p-value = 0.0233; Group 1 vs. Group 3: p-value = 
0.0003; Group 2 vs. Group 3: p-value = 0.002). This difference 
could not be attributed to the chemotherapy added during 
the induction scheme as no significant difference was found 
for patients who received chemotherapy comparing the three 
groups (Group 1 vs. Group 2: p-value = 0.582; Group 1 vs. Group 
3: p-value = 0.431; Group 2 vs. Group 3: p-value = 0.825) (A).33
Leukemia-Cooperative Group (AMLCG) Protocol] (B).27 The first 
cycle consisted of 6-thioguanine (100 mg/m2 b.i.d. orally on D3 
to D8), cytarabine (100 mg/m2/day as a continuous infusion 
on D1 and D2 followed by 100 mg/m2 b.i.d. on D3 to D8) and 
daunorubicin (60 mg/m2/day on D3 to D5). If the patient’s 
doctor knew that the patient would tolerate a second induction 
cycle, this was conducted with cytarabine (1 g/m2 b.i.d. from 
D1 to D3) and mitoxantrone (10 mg/m2 on D1 to D3) (B).27 The 
CR rate was 82% and the early death rate was 18%. The deaths 
occurred between 2 to 19 days after the beginning of induction 
therapy with the death rate being higher in patients with 
leukocyte counts > 10 × 109/L (p-value = 0.009) and in patients 
over 70 years of age (p-value = 0.048). The main causes of death 
were bleeding, multiple organ failure and sepsis (B).28
One hundred and one patients aged from 19 to 73 years with 
APL confirmed by cytogenetics or a molecular study underwent 
induction treatment with ATRA (45 mg/m2/day) until CR, 
idarubicin (12 mg/m2 for under 61-year-old patients on D2, D4, 
D6 and D8 - 9 mg/m2 for patients from 61 to 70 years old and 6 
mg/m2 for over 71-year-old patients), and prednisone (50 mg/
day) if the WBC count was > 10 × 109/L at diagnosis (APML3 
Protocol); 8% died within the first 30 days of treatment with 
the main causes being bleeding, Differentiation syndrome, 
multiple organ failure and sepsis. Differentiation syndrome 
is formally known as ATRA syndrome. The CR rate was 90%. 
The 4-year DFS rate was estimated at 69.7% and 4-year OS was 
estimated at 83.7% (B).29
The AIDA 0493 Protocol with ATRA (45 mg/m2/day) until 
CR or for a maximum of 90 days and idarubicin (12 mg/m2 on 
D2, D4, D6 and D8) in the induction therapy and three cycles 
of consolidation with idarubicin and cytarabine (Cycle 1), 
etoposide and mitoxantrone (Cycle 2) and idarubicin, cytarabine 
and 6-thioguanine (Cycle 3) followed by randomization for 
maintenance was used in 828 under 75-year-old patients 
diagnosed with APL confirmed by cytogenetics or a molecular 
study. The CR rate was 94.03%; 5.45% died during induction and 
0.25% of cases were considered resistant to initial treatment. 
The main causes of deaths during the induction therapy were 
bleeding (70.8%), infections (13.6%), thromboembolism (6.8%) 
and Differentiation syndrome (6.8%). The 12-year EFS and OS 
were estimated at 68.9% and 76.5%, respectively (B).30
The PETHEMA Group evaluated 732 patients with APL 
confirmed by molecular biology and cytogenetics treated 
between 1996 and 2005. The treatment protocol included an 
induction phase, consolidation and maintenance. Induction 
consisted of ATRA (45 mg/m2/day) until CR or a maximum 
of 90 days and idarubicin (12 mg/m2/day on D2, D4, D6 and 
D8). Consolidation consisted of three cycles of ATRA and 
chemotherapy with idarubicin, mitoxantrone or cytarabine 
adapted to the patient’s risk status. Maintenance was with 
6MP, methotrexate and ATRA, and lasted for two years. The 
CR rate was 90.9% and the 5-year EFS and OS were estimated 
at 75% and 75%, respectively for the LPA96 Protocol and 83% 
and 81%, respectively for the LPA99 Protocol (B).18
The LPA93 Protocol consisted of ATRA (45 mg/m2/day) until 
CR or for a maximum of 90 days, cytarabine (200 mg/m2/day 
by continuous infusion) for seven days and daunorubicin (60 
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In the evaluation of peripheral blood, the platelet count 
normalized first in Group 3 (median: 22 days) followed by Group 
1 (median: 33 days; p-value = 0.03) and Group 2 (median: 33 
days; p-value = 0.031), while the recovery times of hemoglobin 
and WBC were similar between groups (A).33
However, in Group 3, the coagulation time and fibrinolysis 
were only slightly less (median: 10.4; range: 6-19 days) than in 
Groups 1 (median: 11.7; range: 7-22 days) and 2 (median: 12.6; 
range: 8-24 days), without significant difference (A).33
On monitoring residual disease by RT-PCR with 
quantification of the PML-RARα fusion after induction 
treatment, a significant difference was identified between 
the groups (Group 1 vs. Group 2: p-value = 0.013; Group 1 
vs. Group 3: p-value = 0.0092; Group 2 vs. Group 3: p-value = 
0.041). The combined therapy showed no significant increase 
in hyperleukocytosis when compared with monotherapy 
and the presence of hepatic dysfunction was not a reason to 
suspend treatment (A).33 However, it should be pointed out 
that treatment in Group 2 was based on ATRA alone during 
induction, a conduct that differs from current protocols in 
which it is associated to an anthracycline.
In the evaluation of ATRA (25 to 45 mg/m2/day) associated 
with As2O3 (0.15-0.16 mg/kg/day) or As2O3 alone in patients 
with again or relapsed APL, no significant difference was 
found in the CR rate between combination therapy (89.8%) 
and single drug therapy (81.7%) with a mean reduction of 6.51 
days (95% CI: -11.32 to -1.70; p-value = 0.008) to achieve CR with 
combination therapy (A).34
Recommendations
There is no evidence of superiority of As2O3 compared to 
ATRA combined with an anthracycline in the induction 
treatment for APL.
What are the risk factors for the development of 
Differentiation syndrome?
P – Acute promyelocytic leukemia
I – Risk factors
O – Differentiation syndrome
Twenty nine patients aged 16 to 81 years with APL confirmed 
by a molecular study began induction treatment with ATRA (45 
mg/m2/day) associated with idarubicin (12 mg/m2/day) on D3, 
D5, D7 and D9 and prednisone (0.5 mg/kg/day) on D1-D15 (or 
intravenous methylprednisolone in patients who were not able 
to receive oral medications); 48.3% of these patients presented 
Differentiation syndrome without any significant difference 
between patients with leukocytosis (> 10 × 109/L) and those 
without leukocytosis (B).35
The risk of developing Differentiating syndrome according 
to the body mass index (BMI) was assessed in 144 patients 
with newly diagnosed APL who received ATRA and idarubicin 
following the AIDA-0493 and Aida-2000 protocols of the 
GIMEMA Group. Four of the underweight (BMI < 18.5 kg/m2) 
and normal patients (BMI: 18-25 kg/m2) patients developed the 
syndrome compared to 21 overweight (BMI: 25-30 kg/m2) and 
obese patients (BMI > 30 kg/m2) and so BMI was identified as an 
independent risk factor for the development of Differentiation 
syndrome (OR: 7.4; 95% CI: 1.0-34.5; p-value = 0.014) (B).36
In the evaluation of 413 patients with newly diagnosed APL, 
15% (95% CI: 12-19) developed Differentiation syndrome during 
the induction treatment. On comparing the leukocyte counts 
at diagnosis (< 5 × 109/L, 5-10 × 109/L, 10-20 × 109/L or > 20 
× 109/L) there was no significant difference between patients 
who developed the syndrome (B).37
In a retrospective analysis of 102 patients diagnosed with 
APL between August 1993 and December 2007 who received 
ATRA (45 mg/m2/day) as induction treatment associated 
to conventional chemotherapy or not, 7.8% developed 
Differentiation syndrome after a median of nine days (range: 
2-23 days) from the beginning of the treatment. Age, gender, 
morphological and molecular subtypes, WBC count at diagnosis 
> 10 × 109/L and chemotherapy were not statistically significant 
risk factors for the development of the syndrome (B).38
Of 39 patients, with a mean age of 26 years diagnosed with 
PML and treated with ATRA and idarubicin according to the 
PETHEMA regimen, 30.5% developed Differentiation syndrome 
(seven severe, four moderate and three fatal cases) within an 
average of 12 days (range: 3-23 days) from the beginning of 
ATRA therapy. Of the patients with BMI ≥ 30, 66.6% developed 
the syndrome compared with 18.5% of patients with BMI 
< 30 (p-value = 0.012). Other predictors of Differentiation 
syndrome in the univariate analysis were: age ≥ 40 years 
(p-value = 0.033), baseline leukocyte count ≥ 20 × 109/L (p-value 
= 0.003) and creatinine > 1.4 mg/dL (p-value = 0.009). However, 
in the multivariate analysis, only BMI ≥ 30 (p-value = 0.044) 
and baseline leukocyte count ≥ 20 × 109/L (p-value = 0.025) 
remained as independent predictors for the development of 
Differentiation syndrome (B).39
In the evaluation of 739 patients with APL, 24.8% developed 
Differentiation syndrome, with 12.6% of severe and 12.2% of 
moderate cases. In multivariate analysis a baseline leukocyte 
count > 10 × 109/L (OR: 1.85; 95% CI: 1.3-2.7; p-value = 0.012) 
and creatinine above normal (OR: 5.8; 95% CI: 1.9 -16.9; p-value 
= 0.004) were associated with increased risk of developing 
Differentiation syndrome; this was repeated in the univariate 
analysis for the baseline leukocyte count (p-value = 0.03) and 
above normal creatinine levels (p-value = 0.002) (B).40
For patients between seven and 34 years of age treated with 
ATRA associated with systemic chemotherapy, there was a 
higher incidence of Differentiation syndrome in those with 
WBC counts at diagnosis > 10 × 109/L, however, this was not 
statistically significant (p-value = 0.08) (C).41
Recommendations
Leukocytosis is a predictor for the development of 
Differentiation syndrome when the WBC count is > 20 × 109/L. 
A BMI above 30 and creatinine above the normal value are 
predictors for the development of Differentiation syndrome. 
There is no evidence for age, gender, morphological and 
molecular subtypes and concomitant systemic chemotherapy 
as risk factors for the development of the syndrome.
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Is the prophylactic use of corticosteroids in 
patients with acute promyelocytic leukemia able 
to prevent Differentiation syndrome?
P – Acute promyelocytic leukemia/Differentiation syndrome
I – Corticosteroid, prophylaxis
C – All-trans retinoic acid
O – Prevent Differentiation syndrome
Differentiation syndrome is the main complication 
associated with therapy using agents that promote 
differentiation, such as ATRA and As2O3, during induction 
therapy of APL. ATRA is well tolerated, however the incidence 
of Differentiation syndrome has been described in up to 27% 
of cases of APL (B).37,38,42 In most reported cases, symptoms 
relating to Differentiation syndrome began in a median of nine 
days (range: 0-23 days) from the start of treatment (B).38
In patients with APL treated with ATRA (45 mg/m2/day) 
initiated within the first 24 to 48 hours after diagnosis, 48.3% 
evolved Differentiation syndrome according to the criteria of 
Frankel (three of the following signs in the absence of other 
causes: fever, weight gain, pulmonary infiltrate, pericardial or 
pleural effusion, hypotension, liver failure and/or acute renal 
failure) with 37.9% of early deaths (B).43
On suspicion of symptoms related to Differentiation 
syndrome, the early addition of high doses of dexamethasone 
reduces associated mortality from 30 to 5% or less (B).44 
It is recommended to start dexamethasone using an 
intravenous dose of 10 mg b.i.d. until total regression of the 
symptoms. Most patients present a rapid improvement with 
the administration of the corticosteroid. The preemptive 
use of corticosteroid early after the start of the clinical 
manifestations of Differentiation syndrome is the standard 
recommended treatment however its prophylactic use is still 
quite controversial. There is only one work of the Australian 
Group in which prednisolone (75 mg/day) was administered 
prophylactically in 12 of 19 (63%) patients being treated with 
ATRA; a reduction in pulmonary toxicity was demonstrated 
in patients with leukocyte counts > 10 x 109/L(B).45 Based on 
this result, the Spanish group started three clinical trials to 
evaluate the impact of prophylaxis with corticosteroids in 
patients with APL and WBC counts > 5 × 109/L at diagnosis.46 In 
the LPA96 study, all patients with leucocyte counts > 5 × 109/L 
before or during the institution of therapy with ATRA received 
prophylaxis with an intravenous dose of dexamethasone (10 
mg b.i.d.) for seven days and the incidence of Differentiation 
syndrome was 30%. The LPA99 study advocated the use of 
prophylaxis with oral prednisone at a dose of 0.5 mg/kg/day 
from D1 to D15 of the protocol for all patients and observed 
an incidence of Differentiation syndrome of 23%. In the 
LPA2005 study, prophylaxis was administered only to patients 
with leukocyte counts > 5 × 109/L. These patients received 
dexamethasone at a dose of 2.5 mg/m2 b.i.d. during 15 days, 
resulting in 28% of Differentiation syndrome. A retrospective 
comparison of these three clinical trials showed a slight 
reduction in the incidence of Differentiation syndrome, 
however it showed no reduction in mortality related to this 
syndrome (B).41,47
Recommendations
So far, there is no evidence supporting the prophylactic use of 
corticosteroids in patients with APL to prevent Differentiation 
syndrome.
What is the best therapeutic conduct for 
Differentiation syndrome?
P – Differentiation syndrome
I – Corticosteroid, diuretics, interruption of ATRA
O – Improvement in symptoms
In a retrospective study of a series of 102 patients with APL 
treated initially with ATRA (45 mg/m2/day), eight patients 
(7.8%) presented Differentiation syndrome based on the 
clinical manifestations following the criteria of Frankel. 
Symptoms suggestive of the syndrome began in a median of 
nine days after starting treatment (range: 2-23 days) with the 
most common being fever (87.5%) and respiratory dysfunction 
(87.5%) (B).38
There was no statistically significant difference for 
gender and age, morphological variant and the isoforms of 
PML-RARα fusion gene transcript in patients who developed 
Differentiation syndrome compared to those who did 
not. None of the patients with APL and a clinical picture 
suggestive of Differentiation syndrome had a leukocyte 
count > 10 × 109/L at diagnosis and there was no relationship 
between patients treated with ATRA alone or combined with 
systemic chemotherapy (p-value = 1.00) (B).38 In this series, 
Differentiation syndrome improved after the interruption of 
ATRA associated with intravenous dexamethasone (20 mg 
b.i.d.) until total regression of symptoms.
In the experience of the PETHEMA group, one quarter of 
the patients with APL under treatment with ATRA developed 
Differentiation syndrome within 7 to 12 days after starting 
the induction phase of treatment. All patients presented 
with respiratory disorders, unexplained fever, weight gain, 
edema, pleural effusion and pulmonary infiltrate. The most 
serious Differentiation syndrome occurred early, on average 
in six days accompanied by acute renal failure. The diagnosis 
of Differentiation syndrome was established by clinical 
manifestations, according to the criteria of Frankel, associated 
with radiological findings of pulmonary infiltrate. The 
recommendation of the Spanish group for the management 
of Differentiation syndrome is the immediately introduce 
intravenous dexamethasone (20 mg/day) and diuretics until 
improvement of the symptoms; ATRA should be discontinued 
in cases of severe respiratory dysfunction syndrome, 
hypotension or renal failure (B).42
In the evaluation of 413 patients with APL, confirmed by 
the presence of the t (15; 17), 64 patients (15%; 95% CI: 12-19) 
developed Differentiation syndrome during the induction 
treatment with the onset of symptoms from one to 35 days 
after beginning the treatment (median: 7 days) (B).37
The most frequent manifestations were respiratory 
dysfunction (89%), fever (81%), pulmonary infiltrate (81%), 
weight gain (50%) pleural effusion (47%), kidney disease (39%) 
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pericardial effusion (19%) and hypotension (12%). On suspicion 
of the diagnosis of Differentiation syndrome, 84.37% of the 
patients received intravenous dexamethasone (10 mg b.i.d.) for 
three to 23 days (median: six days) with suspension of ATRA in 
the most severe cases (46.87%). The Differentiation syndrome-
related mortality rate was 8% in this study. Fifty-five patients 
(86%) with the syndrome achieved CR compared with 94% of 
the group without the syndrome (B).37
Differentiation syndrome occurred in 183 (24.8%) of the 
739 cases of the LPA96 and LPA99 studies. In 93 patients 
(12.6%) symptoms were severe in particular with respiratory 
dysfunction (dyspnea) in 95% of cases, accompanied by 
pulmonary infiltrate, fever, kidney injury and pleural effusion. 
ATRA was suspended in 60% of the cases of the syndrome 
(p-value < 0.001); dexamethasone (10 mg b.i.d.) was prescribed 
for 90% of the patients (p-value < 0.001) and diuretics for 87% 
(p-value < 0.001). Dialysis was performed in 12% of the cases 
(p-value = 0.003) and mechanical ventilation in 26% (p-value 
= 0.002). There were 26% of deaths during the induction 
treatment with 11% due to Differentiation syndrome (B).40
In the evaluation of 29 patients with APL with a mean age 
of 48 years treated with ATRA (45 mg/m2/day) initiated in 24 
to 48 hours after diagnosis, 48.3% developed Differentiation 
syndrome according to the criteria of Frankel (B).43 In this 
series, 10 of 14 (71.4%) patients suffered acute renal failure and 
of these 60% required dialysis. Kidney failure contributed to the 
mortality. The author suggests that therapy with corticosteroid 
(dexamethasone – 20 mg/day) and the suspension of ATRA are 
effective measures against Differentiation syndrome. 
The consensus of experts from the European LeukemiaNet 
recommends that intravenous dexamethasone (20 mg 
b.i.d.) should be started immediately on suspicion of any 
one of the signs or symptoms of Differentiation syndrome 
(dyspnea, unexplained fever, weight gain, peripheral edema, 
hypotension, renal failure, congestive heart failure, and 
particularly a chest x-ray showing lung infiltrate or pericardial 
effusion) (D).8
Recommendations
On suspicion of Differentiation syndrome, immediately start 
intravenous dexamethasone (20 mg b.i.d.) and use for at least 
three days or until total regression of the symptoms. Diuretics 
should be used to maintain a neutral or negative water 
balance. Suspension of ATRA is indicated only in the most 
serious cases with need of treatment in the intensive care 
unit for respiratory distress (dyspnea and hypoxemia), acute 
renal failure or hypotension. ATRA should be interrupted for 
48-72 hours and reintroduced at a 50% dose with stepped 
increases until the full dose.
What is the best therapeutic conduct for 
pseudotumor cerebri syndrome?
P – Pseudotumor cerebri syndrome in patients with acute 
promyelocytic leukemia
I - Corticoid
Pseudotumor cerebri is characterized by increased 
intracranial pressure with the presence of papilledema, normal 
or diminished ventricles and with normal cerebrospinal fluid 
(CSF). Diagnosis is by the modified Dandy criteria which 
includes signs and symptoms of raised intracranial pressure, 
lack of localizing findings in the neurological examination, 
the absence of deformities or obstructions of the ventricular 
system or any other change in the neuroimaging study, except 
for changes in visual acuity and eye movement and increased 
CSF pressure with no other causes of increased intracranial 
pressure (C).48
Among the drugs that are associated with the appearance 
of pseudotumor is ATRA; this adverse effect more commonly 
appears in children (C).48,49
In the evaluation of patients with de novo or relapsed APL 
two days to six months after starting treatment with ATRA, 
the following signs and symptoms suggest a diagnosis of 
pseudotumor cerebri: appearance of symptoms suggestive 
of increased intracranial pressure such as headaches, 
blurred vision, diplopia, nausea and vomiting, with bilateral 
papilledema, normal computed tomography and magnetic 
resonance imaging results and a lumbar puncture with 
CSF with absence of cells and normal glucose and protein 
concentrations, but with increased pressure (C).50-62
In all cases there was an improvement of symptoms in two 
to 28 days after the suspension of ATRA (C).50-62
There is a description of the use of mannitol and 
acetazolamide together with the suspension of ATRA to 
decrease the CSF pressure improving the headaches, diplopia, 
nausea and vomiting in two days and improvement of 
papilledema in seven days (C).62 Moreover there is a description 
of removal of CSF without suspension of ATRA which improved 
the symptoms (C).54
Recommendations
The temporary suspension of ATRA is recommended 
when there is diagnostic suspicion of pseudotumor cerebri 
in patients with APL. ATRA can be reintroduced after 
improvement of the symptoms.
Is prophylaxis of the central nervous system 
indicated for a specific group of patients with 
acute promyelocytic leukemia?
P – Acute promyelocytic leukemia
I – Methotrexate or cytarabine
O – Prophylaxis of the central nervous system
Although the relapse rate in the CNS is low (0.6-2.0%), it is 
the most common extramedullary site for relapse of APL and 
at least 10% of relapses involve in the CNS (D).63
In the evaluation of adult patients with relapse of APL with 
leptomeningeal involvement (without prior CNS involvement), 
the initial treatment is a dose of triple intrathecal therapy 
(methotrexate, cytarabine and hydrocortisone) on the day 
of the diagnostic lumbar puncture before starting therapy 
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with liposomal cytarabine associated with dexamethasone to 
prevent aracnoiditis (C).64
In a follow-up of 70 months, 23% of adult APL patients in CR 
relapsed, with 6% involving extramedullary sites. Of the cases 
of relapse in extramedullary sites, 90% involved the CNS and 
10% the skin. The median WBC count at diagnosis of these 
patients was 26.95 × 109/L (range: 7.7-162 × 109/L), with 80% 
having counts above 10 × 109/L, 30% with APL variants, and 
in the evaluation of the breakpoint of the PML-RARα fusion 
transcript, 30% had the bcr-1 isoform and 60% the bcr-3 
isoform. Bone marrow involvement is documented in 89% of 
relapses in the SNC (B).65
A univariate analysis in this same study identified the 
following risk factors related to extramedullary relapse: age 
less than 45 years (p-value = 0.05), the presence of the PML-
RARα bcr-3 isoform (p-value = 0.0003) and high WBC count 
at diagnosis (p-value < 0.0001). Differentiation syndrome was 
not associated with increased risk of extramedullary relapse 
(p-value = 0.69) (B).65 In multivariate analysis, only the high 
WBC count at diagnosis (p-value = 0.0014) was associated 
with relapse at an extramedullary site. However, whether 
to routinely perform prophylaxis or not of the SNC against 
relapse using intrathecal chemotherapy or high-dose ARA-C in 
patients with leukocyte counts above 10 × 109/L at diagnosis is 
not yet completely defined (B).8 In protocols where prophylaxis 
is made with intrathecal chemotherapy, this must be carried 
out after obtaining a CR as a lumbar puncture at diagnosis and 
during induction can be extremely risky (D).8
Another study that evaluated 739 patients treated with 
idarubicin and ATRA also showed that relapse-free survival 
in patients with or without Differentiation syndrome is 
similar. None of the ten patients who had relapsed in the SNC 
presented with Differentiation syndrome (B).40
In the APL2000 study of the European Group, under 60-year-
old patients with leukocyte counts > 10 × 109/L received a higher 
dose of ARA-C and prophylaxis of the SNC [five applications of 
methotrexate (15 mg), ARA-C (50 mg) and corticosteroid IT)] in 
the second consolidation cycle and over 60-year-old patients 
received prophylaxis of the SNC alone. The rate of relapse in 
the under 60-year-old group was 2.9% and there was no relapse 
in the SNC (B).66
Recommendations
There is no evidence to recommend prophylaxis of the CNS 
in APL patients.
Are there benefits with the use of cytarabine in 
acute promyelocytic leukemia?
P – Acute promyelocytic leukemia
I – Cytarabine
O – Complete remission, disease-free survival, overall 
survival
ATRA in association with an anthracycline is the standard 
treatment for the induction phase of the treatment of APL 
(2A).8 In the study carried out by Adès et al., under 60-year-
old patients diagnosed with APL and with WBC counts 
< 10 × 109/L were randomized to two groups.67 Standard 
induction treatment included ATRA (45 mg/m2/day) until CR 
in combination with daunorubicin (60 mg/m2/day) for three 
days. For one group, cytarabine (200 mg/m2/day) for seven days 
was associated starting on the third day after the beginning 
of ATRA administration. In a 35-month follow-up, the CR rate 
was 96.5%. In the group that received cytarabine the CR was 
99% and for the group without cytarabine it was 94%, without 
statistical significance (p-value = 0.12) (A).67 The molecular 
remission rate was 90% in the group that received cytarabine 
and 82% for patients who did not (p-value = 0.18) (A).67 These 
results were corroborated by the PETHEMA study of the Spanish 
group that, even though it did not investigate the effect of 
the association of cytarabine to standard induction treatment 
(ATRA and anthracycline), reported CR rates of between 90% 
and 95% in patients with APL treated exclusively with ATRA 
and anthracycline (C).18,68 The remission rate reported by the 
international consortium for Acute promyelocytic leukemia in 
180 Brazilian, Chilean, Mexican or Uruguayan patients treated 
with ATRA (45 mg/m2/day until CR) and daunorubicin (60 mg/
m2/day on D2, D4, D6 and D8) was 85% (C).31
With regard to consolidation therapy for APL, most studies 
after the 1990s followed the concept of treatment adapted 
to the risk of relapse (A).18,30,69,70 Patients are classified 
at diagnosis as low, intermediate or high risk for relapse 
according to the leukocyte and platelet counts. The proposal 
that is most widely used is that reported by the PETHEMA and 
GIMEMA studies: low-risk patients have leukocyte counts < 
10 × 109/L and platelet counts ≥ 40 × 109/L, intermediate-risk 
patients have leukocyte counts < 10 × 109/L and platelet counts 
< 40 × 109/L, and high-risk patients have leukocyte counts > 
10 × 109/L.18,30
In under 60-year-old patients with APL in CR after induction 
treatment with ATRA and idarubicin, the association of 
cytarabine or not was compared in the consolidation therapy 
of high-risk patients; the group that did not receive cytarabine 
was followed up for 82 months and the group that received the 
medication was followed up for 28 months (A).70 Three cycles 
of consolidation therapy were used, with the second cycle with 
mitoxantrone (10 mg/m2/day) for five days being similar in the 
two groups. In the first cycle, Group 1 received idarubicin (7 
mg/m2/day) for four days and Group 2 received idarubicin (5 
mg/m2/day) associated with cytarabine (1 g/m2/day) for four 
days. In the third cycle, Group 1 received idarubicin (12 mg/
m2/day) for two days and Group 2 received idarubicin (12 mg/
m2/day) for one day associated with cytarabine (150 mg/m2 
t.i.d.) for four days. Fifteen days of ATRA (45 mg/m2/day) was 
included in all three cycles (A).67 Although thrombocytopenia 
and neutropenia were more common in Group 2 that 
received cytarabine (p-value < 0.001), there was no significant 
difference in CR (81% vs. 83%, respectively) or OS (71% vs. 
79%, respectively; p-value = 0.34). However, the cumulative 
incidence of relapse at three years was significantly lower in 
the group that received cytarabine (26% vs. 11%, respectively; 
p-value = 0.03) (A).70
The German group studied the role of cytarabine in treating 
under 60-year-old patients with APL. Patients were treated with 
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idarubicin and ATRA in the induction phase and evaluated in 
the consolidation phase on a cycle of idarubicin (12 mg/m2/
day) on D1, D3 and D5, cytarabine (100 mg/m2/day) as seven 
days of continuous infusion and etoposide (100 mg/m2/day) 
for three days and two cycles of cytarabine (3 g/m2 b.i.d.) for 
three days associated with mitoxantrone (10 mg/m2/day) for 
two days (B).18 The CR rate was 88% and the mortality rate 
during treatment was 12%. The DFS and OS, after a follow-up 
period of 46 months, were 83% and 82%, respectively (B).71
Recommendations
The association of cytarabine to an anthracycline and ATRA 
in the consolidation therapy of patients diagnosed with APL 
is recommended for under 65-year-old high-risk patients 
based on the significant reduction in the relapse rate and the 
significant increases in EFS and OS. There is no evidence to 
support this association for intermediate- or low-risk patients.
What is the role of transplantation in relapse 
of acute promyelocytic leukemia and when 
should allogeneic and autologous transplants be 
indicated?
P – Acute promyelocytic leukemia
I – Allogeneic transplant 
C – Autologous transplant
O – Complete remission, disease-free survival, overall survival
In a retrospective study, 73 of 122 (60%) patients with 
relapsed APL who achieved a second complete hematological 
remission underwent bone marrow transplantation (BMT). Fifty 
patients (median age: 45 years) were submitted to autologous 
BMT and 23 (median age: 32.5 years) to allogeneic BMT. For 
those who underwent autologous BMT, the DFS, EFS and OS 
at seven years were 79.4%, 59.4% and 60.6%, respectively, with 
6% of transplant-related deaths, 2% of deaths due to lung 
cancer 49 months after the BMT, 6% of relapse three to 18 
months after the BMT and 4% of myelodysplastic syndromes 
(SMD) (B).72 For patients who underwent allogeneic BMT, the 
DFS, EFS and OS at seven years were 92.3%, 52.2% and 51.8%, 
respectively, with 39% of transplant-related deaths, 4.3% of 
deaths from non-Hodgkin’s lymphoma and 4.3% of relapse 
after 17 months of the BMT (B).72 Forty-nine patients (median 
age: 45 years) were treated with systemic chemotherapy after 
the second remission with 10.2% of treatment-related deaths 
and 53% of relapse after two to 22 months. In the case of 
systemic chemotherapy the DFS, EFS and OS were 42.7%, 37.4% 
and 46%, respectively (B).72 The OS was significantly higher for 
patients who underwent autologous BMT (p-value = 0.04) while 
there was no significant difference for DFS and EFS between 
autologous or allogeneic BMT (p-value = 0.19 and p-value = 
0.11, respectively). The DFS, EFS and OS were also significantly 
higher in patients who underwent autologous BMT compared 
to patients who received systemic chemotherapy (p-value = 
0.002, p-value = 0.0005 and p-value = 0.001, respectively). The 
EFS and OS were similar in the groups of patients who received 
allogeneic BMT and systemic chemotherapy (p-value = 0.17 and 
p-value = 0.41, respectively), but the DFS was better in those 
who received allogeneic BMT (p-value = 0.0018) (B). 72
These data suggest that autologous BMT is very effective in 
the treatment of APL for patients in second complete molecular 
remission. Allogeneic BMT, though with a lower relapse rate, is 
associated with high transplant-related mortality (B).72
The European Group for Bone Marrow Transplant evaluated 
625 patients with APL after 1993 who received autologous or 
allogeneic BMT after the first or second CR. The DFS at five years 
was 69% for the 149 patients in first remission who underwent 
autologous BMT and 68% for the 144 who underwent allogeneic 
BMT. The DFS after the second remission was 51% for the 195 
patients who were submitted to autologous BMT and 59% for 
the 137 patients who underwent allogeneic BMT. The data lead 
to the conclusion that transplants still seem to have a role to 
play in APL, especially for patients in second remission (B).73
A retrospective analysis was performed of 32 patients aged 
between one and 16 years diagnosed with relapsed APL or 
disease refractory to the first treatment and who underwent 
autologous (n = 11) or allogeneic BMT (n = 21). In the case of 
autologous BMT, treatment-related mortality was 0% (95% 
CI: 0-30) and the relapse rate was 27% (95% CI: 9-57) and for 
allogeneic BMT, treatment-related mortality was 19% (95% CI: 
7-41) and the relapse rate was 10% (95% CI: 2-30). The mean 
times to relapse were 15.3 months (range: 4.4-42.7 months) 
and 13.5 months (range: 7.3-19.6 months) for autologous and 
allogeneic BMT, respectively. The EFS at five years was 73% for 
autologous BMT and 71% for allogeneic BMT (p-value = 0.81) 
and the OS was 82% and 76%, respectively (p-value = 1.0) (B).74
The European Group of Hematopoietic Stem Cell 
Transplantation recommends autologous BMT or a transplant 
with a HLA-identical related donor for cases of APL in second 
CR and BMT with a HLA-identical related donor in the case of 
molecular persistent APL (D).75
Recommendations
In APL, autologous hematopoietic stem cell transplant is 
accepted for patients in second complete molecular remission.
How to make the diagnosis of molecular 
relapse? Which method, quantitative or 
qualitative polymerase chain reaction, is most 
recommended?
P – Acute promyelocytic leukemia
I – Quantitative polymerase chain reaction, 
C – Qualitative polymerase chain reaction
O – Molecular relapse
For patients with APL initially treated with As2O3 (27.2% 
low-risk and 72.8% high-risk), RT-PCR and quantitative real 
time polymerase chain reaction (RQ-PCR) was performed at 
diagnosis, at the end of induction treatment, at the beginning 
of the consolidation phase and every three months during 
the two years of maintenance treatment with subsequent 
evaluation for the presence of PML-RARα transcripts to assess 
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minimal residual disease (MRD) and its predictive effect on 
relapse (B).76
For both groups, the results were positive for PML-RARα 
using RT-PCR and RQ-PCR in 100% of cases at diagnosis, 63.82% 
and 85.18%, respectively at the end of the induction treatment 
(at this time there was 100% of complete hematological 
remission), 19.49% and 34.78%, respectively before the 
beginning of the consolidation treatment and 0% and 27.11%, 
respectively during maintenance treatment (B).76
In multivariate analysis, there was a 4.8-fold higher risk of 
relapse in patients with positive RT-PCR results at the end of the 
induction treatment compared to patients negative for the PML-
RARα (95% CI: 1.13-21.19; p-value = 0.034), without significant 
impact on the risk of relapse at the beginning of the consolidation. 
The sensitivity, specificity and VR that a positive RT-PCR predicted 
relapse after induction were 86.7%, 42.3% and 1.50, respectively; 
and the sensitivity, specificity and VR that a positive RQ-PCR 
predicted relapse were 89.3%, 19.2% and 1.10, respectively (B).76
On comparing FISH with RT-PCR for the diagnosis and 
monitoring of APL, failures to identify disease were seen in 8% 
and 4%, respectively at diagnosis, in 38% and 13%, respectively 
at the end of induction and in 66% and 0%, respectively at 
the end of the consolidation treatment. All cases that were 
negative by RT-PCR and FISH at the end of the induction 
and consolidation remained in molecular remission over 18 
months of follow-up. The predictive values for relapse at the 
end of induction in patients with positive and negative RT-PCR 
results were 60 ± 11% and 3%, respectively; for the positive and 
negative FISH testing results, these values were 57 ± 13% and 
6%, respectively (B).77
In assessing the MRD in APL with RQ-PCR, values ≥ 1 × 10-3 
after the end of consolidation treatment compared with values 
< 1 × 10-3 proved to be the most important predictor of relapse 
(85.7 ± 13.2% vs. 7.3 ± 4.1%; p-value < 0.001) and DFS (14.3 ± 
13.2% vs. 91.2 ± 4.3%; p-value < 0.001) (B).78
The molecular response of patients with APL was evaluated by 
RT-PCR and RQ-PCR after induction and consolidation treatment. 
For RT-PCR, positive and negative results were defined as the 
presence or absence of PML-RARα transcripts and for RQ-PCR, a 
minor response was defined when the level was between log 3.0 
and 4.9 and a major response when the level was ≥ log 5.0 (B).79
After completion of the induction treatment, negative 
responses by RT-PCR and minor and major molecular responses 
by RQ-PCR were 35.5%, 22.6% and 12.9%, respectively. After 
consolidation treatment these responses were 96.8%, 96.8% and 
90.3%, respectively. The time of treatment to attain negative 
results by RT-PCR was on average two months compared 
to three months to acquire a minor molecular response by 
RQ-PCR (p-value = 0.56) and four months to acquire a major 
molecular response (p-value = 0.0036) (B). 79
No association between a positive RQ-PCR result and relapse 
of the disease were found for patients aged between eight 
the 84 years with molecular diagnosis of APL after induction 
treatment. However, after the third cycle of consolidation, 66% 
of cases with positive RQ-PCR results relapsed compared to 
13% of patients with negative RQ-PCR results. Around 23% of 
the cases that presented with hematologic relapse were not 
predicted by molecular techniques (RT-PCR or RQ-PCR). In all 
these cases, consistent analysis had been performed four to five 
months before relapse (mean: 260; range: 153-386 days) (B).80
Recommendations
Molecular diagnosis of relapse in APL can be performed by 
FISH, RT-PCR and RQ-PCR; RQ-PCR is the most important to 
predict hematologic relapse and DFS.
What are the best therapeutic options for 
hematologic and extramedullary relapse?
P – Relapse or recurrence and acute promyelocytic leukemia
I – All-trans retinoic acid or arsenic trioxide or systemic 
chemotherapy
O – Remission
Relapse was seen in 23% of cases of adult patients with APL 
in CR; 6% were extramedullary in a follow-up of 70 months. 
Of the relapse cases in extramedullary sites, 90% involved the 
CNS and 10% involved the skin. The median WBC count of 
these patients at diagnosis was 26.95 × 109/L (range: 7.7-162 
× 109/L) with 80% having counts > 10 × 109/L, 30% with APL 
variants, and in the evaluation of the breakpoint of the PML-
RARα fusion transcript, 30% have the bcr-1 isoform and 60% 
the bcr-3 isoform. Bone marrow involvement is documented 
in 89% of the relapses of the SNC (B).65
A univariate analysis in this same study identified the 
following risk factors related to extramedullary relapse: age 
less than 45 years (p-value = 0.05), the presence of the PML-
RARα bcr-3 isoform (p-value = 0.0003) and high WBC count 
at diagnosis (p-value < 0.0001). Differentiation syndrome was 
not associated with increased risk of extramedullary relapse 
(p-value = 0.69) (B).65 In the multivariate analysis, only the 
high WBC count at diagnosis (p-value = 0.0014) was associated 
with relapse at an extramedullary site and so, for prophylaxis 
against CNS involvement with intrathecal chemotherapy is 
indicated in cases of leukocyte counts > 10 × 109/L at diagnosis 
(B).65
The treatment for relapse in SNC included triple intrathecal 
therapy in all cases associated with ATRA in 55.5% of the 
patients. Systemic chemotherapy was added as rescue therapy 
in 88.9% of the cases: an anthracycline (mitoxantrone or 
idarubicin) with high- or intermediate-dose cytarabine. Eleven 
percent of the patients with CNS involvement who entered 
in second CR performed irradiation as consolidation of the 
retreatment. The 10% of cases who had skin involvement 
performed irradiation without systemic chemotherapy, 
followed by maintenance treatment using low-dose cytarabine 
and intermediate-dose ATRA (B).65
Of all the cases of relapse, 30% died due to bleeding from 
the CNS or sepsis during rescue treatment and 70% attained 
a second CR. Of these, 30% underwent allogeneic BMT and 
30% autologous BMT. The median survival of patients with 
extramedullary relapse was 6.7 months compared to 26.3 
months when relapse involved the bone marrow in isolation 
(p-value = 0.04) (B).65
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100% had C-sections or normal births and 77.8% were treated 
with ATRA alone (D).83-92 All women showed significant 
improvement of the management of bleeding disorders at 
varying degrees after the first week of treatment, especially 
those receiving ATRA in isolation or associated with other 
medications (C).83-92
Of all patients, regardless of the gestational age at diagnosis, 
83% achieved CR after induction treatment (C).83
Due to the teratogenic potential of ATRA and As2O3, both 
should be avoided during the first trimester of pregnancy 
and As2O3 throughout the pregnancy. Administration of 
chemotherapy during the first trimester, although it may be 
safe, is also associated with fetal malformations, increased 
risk of miscarriage and low birth weight (C).93 The decision 
at this stage of pregnancy is to interrupt the pregnancy while 
there is hemodynamic stability to start treatment with ATRA 
in combination with chemotherapy or to continue with the 
pregnancy and prescribe anthracycline, starting with ATRA 
earlier in the second quarter. In this case the recommended 
anthracycline is for daunorubicin as it is effective in APL and 
there is more experience of its use during pregnancy (D).8,94
The use of ATRA is relatively safe for mother and fetus in 
the second and third trimesters93 (C) and there is no evidence 
of fetal malformations, although reversible fetal arrhythmias 
and other heart complications have been described at birth and 
so fetal monitoring is recommended during treatment (D).95 
At this stage of pregnancy, you can opt for sequential use of 
ATRA followed by chemotherapy, which would be launched 
after the end of the pregnancy, however taking into account 
the increased risk of the development of differentiation 
syndrome (approximately 25% of cases) (C).96 Another option 
is the simultaneous use of ATRA and chemotherapy, which 
brings higher chances of cure and is a good option for high-risk 
patients with Leukocytosis (D).94
Recommendations
Avoid the use of As2O3 throughout pregnancy and the use 
of ATRA in the first trimester of pregnancy. Daunorubicin is 
recommended in the first trimester. The use of ATRA during 
the second and third trimester of pregnancy seems effective 
to reverse coagulopathies and obtain CR without evidence of 
teratogenicity; it can be associated to chemotherapy or not.
How should an elderly patient with acute 
promyelocytic leukemia be treated?
P – Acute promyelocytic leukemia, elderly
I – All-trans retinoic acid or cytarabine or anthracycline 
(idarubicin or daunorubicin)
O – Complete remission, disease-free survival, overall 
survival
Patients aged 60 to 81 years (median: 65.5 years) with 
diagnosis of APL were treated with ATRA (45 mg/m2/day) 
associated or not with idarubicin (12 mg/m2/day) for four 
days; CR was obtained in 87.5% of cases with a mortality rate 
Patients in first relapse of APL previously treated with 
ATRA and systemic chemotherapy with anthracycline were 
compared with regard to treatment with a 3-hour intravenous 
infusion of As2O3 (0.15 mg/kg/day) in isolation or associated 
with oral ATRA (45 mg/m2/day) started on the first day of 
the administration of the As2O3 until the CR. In patients 
who presented leukocyte counts > 30 × 109/L, daunorubicin 
(60 mg/m2/day) or amsacrine (90 mg/m2/day) for three days 
was associated to the regimen. With no significant difference 
between the groups, 80% of the patients obtained a second CR. 
However, all patients (10%) who did not obtained remission, 
were treated with As2O3and ATRA and the remaining 10% died 
during treatment (A).81
Recommendations
Intrathecal chemotherapy associated with ATRA or As2O3and 
systemic chemotherapy with cytarabine and anthracycline 
are recommended when relapse of APL involves the CNS. If 
the relapse is only hematological, treat with ATRA or AS2O3 
associated with cytarabine and anthracycline.
How should the patient with acute promyelocytic 
leukemia during pregnancy be treated?
P – Pregnant women with acute promyelocytic leukemia
I – All-trans retinoic acid or cytarabine or anthracycline 
(daunorubicin or idarubicin)
O – Complete remission, disease-free survival, overall 
survival
APL has been described in about 10% of cases of leukemia 
during pregnancy, similar to the percentage of leukemias in 
non-pregnant women (D).82
Cases of women diagnosed with APL during gestation have 
been reported and analyzed separately during each trimester, 
taking into account the gestational age of diagnosis, the 
presence of disseminated intravascular coagulation (DIC), the 
treatment regimen employed, the gestational age at vaginal 
birth or C-section, if there were complications to the fetus and 
newborn, incidence of miscarriages and malformations (C).83
Of the women evaluated, 28.6% were in the first trimester 
of pregnancy, 50% in the second trimester and 21.4% in the 
third trimester. All began treatment soon after diagnosis 
with varying schemes: ATRA alone, ATRA associated to 
an anthracycline and/or cytarabine, and/or other systemic 
chemotherapy or chemotherapy without ATRA (C).83-92
Of pregnant women diagnosed in the first trimester, 41.7% 
suffered miscarriages or abortions (for malformations), 50% 
delivered by C-section or vaginal and 8.3% had no details, 
with 50% of these women having been treated with ATRA 
alone or in association with systemic chemotherapy. Of the 
women diagnosed in the second trimester of pregnancy, 76.2% 
delivered by C-section or vaginal birth, 4.8% had miscarriages 
and there were no reports on 19%, with 57.1% having been 
treated with ATRA in isolation or in association with systemic 
chemotherapy. Of the pregnant women of third trimester, all 
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rate was 90% with 10% of deaths during induction treatment 
and 6.6% after remission due to bleeding or infection before 
or during consolidation; 18.3% relapsed after a median time of 
17.5 months of CR. OS, DFS and the cumulative incidence of 
relapse at five years were 76.1%, 64.6% and 27.4%, respectively 
(B).100
Newly diagnosed patients with APL, confirmed by 
cytogenetics or molecular study, aged 60 years or older with 
normal liver and kidney function and without severe heart 
disease or infectious disease at diagnosis were assessed as to 
the response to induction treatment with one or two systemic 
chemotherapy cycles associated with ATRA (45 mg/m2/day) 
until CR or for a maximum of 60 days (B).101
The first cycle comprised oral 6-thioguanine (100 mg/m2 
b.i.d. from D3 to D8), a continuous infusion of cytarabine (100 
mg/m2/day on D1 and D2 followed by 100 mg/m2 b.i.d. on D3 
to D8) and daunorubicin (60 mg/m2/day from D3 to D5). For 
cases that did not obtain remission after induction, a second 
induction cycle was conducted with cytarabine (1 g/m2 b.i.d. 
from D1 to D3) associated with mitoxantrone (10 mg/m2 from 
D1 to D3) (B).101
RC was attained in 82% of patients with early death in 18% 
within two to 19 days after beginning induction therapy. The 
mortality rate was higher for patients with leukocyte counts 
> 10 × 109/L (p-value = 0.009) and in over 70-year-old patients 
(p-value = 0.048). The main causes of death were bleeding, 
multiple organ failure and sepsis (B).101
Recommendations
There is no evidence on which is the best treatment for APL in 
the elderly. Treatment similar to those conducted in patients 
younger than 60 years are recommended but lower response 
to treatment should be expected. The use of cytarabine shows 
no significant benefits in this population. Patients who are 
not eligible for treatment have short survival.
How should minimal residual disease in acute 
promyelocytic leukemia be monitored?
P – Acute promyelocytic leukemia
I – Polymerase chain reaction
O – Minimal residual disease
The investigation of the PML-RARα rearrangement in 
patients with APL in hematologic remission (investigation 
of MRD) is commonly performed by RT-PCR or RQ-PCR. 
Diverio et al. analyzed bone marrow samples harvested 
at different times from 163 patients with APL treated with 
ATRA and anthracyclines. Of the 21 patients who converted 
from a negative to a positive result using RT-PCR, 20 suffered 
hematologic relapse after a median time of three months 
(range: 1-14 months). Of the 142 patients who persisted with 
negative results in RT-PCR tests, eight suffered hematologic 
relapse and 134 remained in CR (B).102
In a group of APL patients (27.2% low-risk and 72.8% high-
risk for relapse) initially treated with As2O3, RT-PCR and 
RQ-PCR were performed at diagnosis, at the end of induction 
of 12.5%. One to three cycles of consolidation treatment and 
maintenance with 6MP plus methotrexate was then carried 
out. In a median follow-up time of 19 months (range: 7-64 
months), the OS and EFS at 24 months were 81.2% and 58.3%, 
respectively (B).97
Patients with again APL aged 60 years or more with t (15; 
17) or PML-RARα rearrangement, normal liver and kidney 
function and without cardiac contraindications for the 
use of anthracyclines, were assessed regarding response 
to chemotherapeutic treatments (B).98 Induction therapy 
consisted of ATRA (45 mg/m2/day) until the CR associated 
with idarubicin (12 mg/m2/day) on D2, D4, D6 and D8 in the 
first 36 months of follow-up (LPA96) or on days D2, D4 and 
D6 in the following 48 months (LPA99). Patients in CR were 
given three cycles of consolidation chemotherapy. The first 
cycle consisted of idarubicin (5 mg/m2/day) for four days, the 
second was with mitoxantrone (10 mg/m2/day) for five days 
and the third was with idarubicin (12 mg/m2/day) for one day. 
Patients who became PML-RARα negative began maintenance 
therapy with mercaptopurine (50 mg/m2/day), intramuscular 
methotrexate (15 mg/m2/week) and ATRA (45 mg/m2/day) for 
15 days every three months for two years (B).98
RC was attained in 84% of patients (95% CI: 77-91) with the 
worst responses rates being observed in patients with platelet 
counts < 40 × 109/L (77% vs. 93%; p-value = 0.076) and in those 
older than 70 years of age (74% vs. 89%; p-value = 0.096) (B).98
Mortality rate of 16.34% was observed during the induction 
treatment with deaths due to infection, pulmonary or cerebral 
hemorrhage and Differentiation syndrome; 3.8% of the deaths 
during consolidation treatment were by lung aspergillosis, 
cardiac dysfunction, brain hemorrhage or pulmonary infection 
and 2.8% of deaths during maintenance treatment were due to 
unrelated accidental trauma or other unknown causes. After a 
mean follow-up of 36 months, the cumulative rate of relapse 
at six years was estimated at 8.5% with 11.2% in patients aged 
60 to 70 years and 0% in those over 70 years of age (p-value = 
0.19). For patients who attained CR, the estimations of DFS and 
leukemia-free survival at six years were 79% ± 10% and 91% ± 
8%, respectively (B).98
In the evaluation of over 60-year-old patients with again 
APL treated with ATRA (45 mg/m2/day) until CR or a maximum 
of 90 days and systemic chemotherapy with daunorubicin (60 
mg/m2/day) for three days and cytarabine (200 mg/m2/day) for 
seven days, the CR rate was 86%. Of the patients in CR, 18.6% 
died mainly due to sepsis during the consolidation cycle which 
consisted in daunorubicin (45 mg/m2/day) for three days and 
cytarabine (1 g/m2 b.i.d.) for four days or during maintenance 
treatment with ATRA, 6MP and methotrexate. The incidence 
of relapse and the EFS and OS rates at four years were 15.6%, 
53% and 57.8%, respectively (B).99
To decrease the toxicity of APL treatment in elderly patients, 
response was assessed after induction with ATRA (45 mg/m2/
day) associated with idarubicin (12 mg/m2/day) on D2, D4, D6 
and D8 (as in young patients), followed by a single cycle of 
consolidation with idarubicin (5 mg/m2) and cytarabine (1 g/
m2) on D1 to D4, and maintenance with ATRA (45 mg/m2/day) 
for 15 days every three months. The hematological remission 
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treatment, at the beginning of the consolidation phase and 
every three months during two years of maintenance treatment 
with subsequent evaluation of PML-RARα transcripts to assess 
MRD and the predictive effect on relapse of the disease (B).76 
The results were positive for the PML-RARα transcript in 100% 
of cases for both RT-PCR and RQ-PCR at diagnosis, 63.82% and 
85.18%, respectively at the end of the induction treatment (at 
this time 100% of patients were in complete hematological 
remission), 19.49% and 34.78%, respectively before the 
beginning of the consolidation treatment and 0% and 27.11%, 
respectively during maintenance treatment (B).76 
MRD monitoring in patients with APL by RQ-PCR using 
peripheral blood and bone marrow after each cycle of 
chemotherapy and every three months after the end of 
consolidation treatment was a strong and independent 
predictor of DFS [hazard ratio (HR): 17.87; 95% CI: 6.88-46.4; 
p-value = 0.0001] better than the leukocyte count (HR: 1.02; 
95% CI: 1.0-1.03; p-value = 0.002) and a strong and independent 
predictor of relapse (HR: 39.94; 95% CI: 11.06-144.18; p-value = 
0.0001) again better than the leukocyte count (HR: 1.03; 95% 
CI: 1.01-1.05; p-value = 0.002) (B).103 The detection of PML-
RARα transcripts at the end of induction alone was not a good 
predictor for DFS (B).103 The serial evaluation of bone marrow 
samples proved to be superior to peripheral blood samples103 
(B) and thus the European LeukemiaNet recommends the study 
of bone marrow every three months (B).8
These results were corroborated by the study by Lee et 
al. in which levels of MRD ≥ 1 × 10-3 of transcripts identified 
by RQ-PCR at completion of the consolidation treatment 
compared with values of < 1 × 10-3 proved to be the most 
important predictor of relapse (85.7 ± 13.2 vs. 7.3 ± 4.1; p-value 
< 0.001) and DFS (14.3 ± 13.2 vs. 91.2 ± 4.3; p-value < 0.001) (B).78
In respect to the molecular diagnosis of APL, 23% of the cases 
that presented with hematologic relapse were not predicted by 
molecular techniques (RT-PCR or RQ-PCR). In all these cases, 
consistent analysis had been performed four to five months 
before relapse (mean: 260; range: 153-386 days) (B).104
Recommendations
The monitoring of MRD should be carried using RT-PCR or 
RQ-PCR molecular tests with serially obtained bone marrow 
samples. It is recommended to test at diagnosis, after 
consolidation and every three months during maintenance 
treatment for two years.
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